Clinical trial · Observational
PRospective Prostate biOmarker Study
PRospective Prostate biOmarker Study (PROPOSe)
NCT03565289CI-TRIAL-00048857PROPOSecompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
• Correlation of a glycoprotein panel with prostate biopsy outcome and PCa aggressiveness
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Indication for Prostate Biopsy Due to Suspected Prostate Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sample collection | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- All patients
- description
- All
- interventionNames
- Diagnostic Test: Blood sample collection
Primary outcomes (4)
- measure
- Diagnosis of PCA
- timeFrame
- 6 months
- description
- Correlation of the glycoprotein panel algorithm with histological diagnosis of PCa
- measure
- Aggressiveness of PCA
- timeFrame
- 6 months
- description
- Correlation of the glycoprotein panel algorithm with diagnosis of significant (Gleason Score ≥7) PCa
- measure
- Diagnosis of PCA
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 45 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Male patient between 45 and 80 years old. * tPSA between 2 and 10 ng/ml * Prostate volume \>=35 ml * Non-suspicious DRE for prostate cancer * Scheduled for prostate biopsy * Patient must give written informed consent Exclusion Criteria: * Patient not undergoing biopsy of the prostate * Prior prostate biopsy within the last 12 months * Transurethral resection of the prostate (TURP) in the last 5 years * Patients with known acute or chronic prostatitis/cystitis or other known prostate abnormalities * Patient taking 5-alpha-reductase inhibitor * Any other prior treatment of the prostate (cryoablation, hifu, ire, radiation therapy, alcohol instillation, etc.)
References
Publications (0)
Data not yet available
No reference posted for this study.